Eli Lilly & Company (LLY) focuses on the development and market distribution of human pharmaceuticals globally, trading under the “LLY” ticker on the NYSE. The current analysis suggests a potential rise between $1144.39 and $1196.17, staying above the low from 12.10.2025 to complete wave ((3)).
The weekly perspective points to a bullish impulse sequence, climbing towards an all-time high. The sequence includes significant levels: $64.18 low in November 2016 for wave (II), $937.96 high in August 2024 for wave (III), and $623.78 low in August 2025 for wave (IV). The wave III of (III) showed the strongest momentum, while the (IV) pullback followed a double correction pattern.
Currently, energy is in the I of (V) rally stage, with wave ((3)) expecting an upward trajectory within the $1144.39 to $1196.17 range. The rally structure contains seven upward swings since the 12.10.2025 low, with two further highs anticipated before the next correction. Strategic buying opportunities might arise during pullbacks in three, seven, or eleven swings corrections in ((4)) or later in II of (V) against the 8.08.2025 low.
Legal disclaimers note market unpredictability, emphasizing self-research prior to any trading decisions.
It looks like Eli Lilly is in a strong upward push, with a target between $1144.40 and $1196.17 in the near future. This view holds as long as we stay above the low set on December 10, 2025. This momentum is part of a larger rally that started back in August 2025.
This technical outlook is supported by strong fundamentals we have seen recently. For instance, the company’s Q3 2025 earnings, reported back in October, showed that sales for its weight-loss drugs beat expectations by over 15%, a trend we expect to continue. Positive early adoption data for its Alzheimer’s drug, Donanemab, further strengthens this bullish case.
For traders using options, this suggests a strategy of buying call options on any small dips in the coming days or weeks. An alternative is to sell cash-secured puts at strike prices below the current market price to collect premium, capitalizing on the expected upward trend. The low market volatility, with the VIX recently dipping below 14, also makes buying options relatively cheaper right now.
We should be prepared for a brief pullback, as the analysis suggests the current leg of the rally is nearly complete before a short correction. This potential dip could be the entry point we are looking for, especially if the price holds above the key support level from December 10, 2025. A break below that level would require us to reassess this bullish outlook entirely.
